NSE: GLAXO | BSE: 500660

Expensive Performer

Download real time

2958.10 20.60 (0.70%)

41.66% Gain from 52W Low

49,843 NSE+BSE Volume

NSE 04 Sep, 2026 3:31 PM (IST)

50,112

Market Cap

High in industry

Beta 1Year

Very Low volatility

GlaxoSmithKline Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAXO, BSE:500660 GlaxoSmithKline Pharmaceuticals Ltd.

Search Inside the pdf :

GlaxoSmithKline Pharmaceuticals Ltd.

03 Aug 2026

2958.10

0.70%

Earnings in line; marketing spend rises with new launches

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GlaxoSmithKline Pharmaceuticals (GLXO) delivered a better-than-expected revenue and in-line EBITDA/PAT in 1QFY27. Revenue tracked high-teen YoY growth after eight quarters of subdued growth.

GlaxoSmithKline has gained 15.11% in the last 1 Month

GlaxoSmithKline Pharmaceuticals Ltd.

09 Nov 2025

2958.10

0.70%

Resilient show on margins despite soft growth

Hold: GlaxoSmithKline Pharmaceut...

Recommendation Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals (GSK) reported weak Q2FY26 result. Revenue growth was negatively impacted due to supply-led issues at a CMO (~INR 400mn) and temporary impact of GST rate cut (~INR 300); adjusting for it, growth in general medicines segment stood at 6-7%.

GlaxoSmithKline Pharmaceuticals Ltd. is trading above all available SMAs

GlaxoSmithKline Pharmaceuticals Ltd.

02 Aug 2025

2958.10

0.70%

Specialty gains offset by base portfolio headwinds

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GlaxoSmithKline Pharmaceuticals (GLXO) delivered lower-than-expected revenue/EBITDA (8%/5% miss) in 1QFY26.

GlaxoSmithKline Pharmaceuticals Ltd. is trading above all available SMAs

GlaxoSmithKline Pharmaceuticals Ltd.

14 May 2025

2958.10

0.70%

Sluggish growth; margins may have hit a peak

Sell: GlaxoSmithKline Pharmaceut...

Recommendation Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSK) Q4FY25 revenue grew at a slower pace of 4.8% due to slowdown in acute therapy market. Improvement in mix led to 340bps YoY expansion in gross margin while cost savings and productivity improvement fuelled 650bps surge in EBITDA margin.

GlaxoSmithKline has gained 36.69% in the last 3 Months

GlaxoSmithKline Pharmaceuticals Ltd.

05 Aug 2024, 12:00AM

2958.10

0.70%

Superior execution and lower RM costs drive earnings

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

Glaxo Pharma (GLXO) delivered better-than-expected 1QFY25 performance. The robust growth in key brands, young potential brands.

GlaxoSmithKline Phar.. has an average target of 2685.00 from 2 brokers.

GlaxoSmithKline Pharmaceuticals Ltd.

05 Aug 2024, 12:00AM

2958.10

0.70%

On road to recovery

Hold: GlaxoSmithKline Pharmaceut...

Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSK) Q1FY25 result was ahead of our expectations driven by mixed improvement and curb in overhead cost.

GlaxoSmithKline Phar.. has an average target of 2685.00 from 2 brokers.

GlaxoSmithKline Pharmaceuticals Ltd.

27 Jul 2023

2958.10

0.70%

Launch cost dents margins

Hold: GlaxoSmithKline Pharmaceut...

Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSKP) Q1FY24 performance was largely in line with expectations, though EBITDA margin was weaker due to marketing cost of the newly launched Shingrix (herpes zoster vaccine). GSKP’s focus on volume growth forms the crux of its market-approach strategy as pricing pressure forces companies to think differently.

GlaxoSmithKline has gained 15.11% in the last 1 Month

GlaxoSmithKline Pharmaceuticals Ltd.

19 May 2023

2958.10

0.70%

Mandated price cuts dampen margins

Hold: GlaxoSmithKline Pharmaceut...

Recommendation Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSKP) Q4FY23 performance was disappointing with margins taking a hit due to unfavourable mix and price cuts on the NLEM portfolio (42% of sales). GSK’s focus on volume growth forms the crux of its market-approach strategy as pricing pressures force it to think differently.